PharmaResources (Shanghai) Co., Ltd. (SHE:301230)
China · Delayed Price · Currency is CNY 45.49
+1.09 (2.45%)
At close: May 12, 2026
SHE:301230 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 691.21 | 688.35 | 529.95 | 480.48 | 472.12 | 446.44 |
Other Revenue | - | - | 14.52 | 9.24 | 6.76 | 1.77 |
| 691.21 | 688.35 | 544.47 | 489.72 | 478.88 | 448.21 | |
Revenue Growth (YoY) | 18.52% | 26.43% | 11.18% | 2.26% | 6.84% | 58.38% |
Cost of Revenue | 495.6 | 499.63 | 413.89 | 350.61 | 304.46 | 278 |
Gross Profit | 195.61 | 188.72 | 130.58 | 139.11 | 174.42 | 170.22 |
Selling, General & Admin | 111.83 | 111.01 | 89.18 | 73.59 | 80.17 | 61.87 |
Research & Development | 39.17 | 37.15 | 47.26 | 37.34 | 32.65 | 17.14 |
Other Operating Expenses | -3.31 | -3.06 | 1.76 | 1.24 | 1.66 | 1.77 |
Operating Expenses | 147.69 | 145.1 | 139.48 | 112.46 | 114.17 | 83.24 |
Operating Income | 47.92 | 43.62 | -8.9 | 26.64 | 60.25 | 86.98 |
Interest Expense | - | - | -9.28 | -5.46 | -4.79 | -2.53 |
Interest & Investment Income | 6.85 | 0.11 | 6.57 | 6.16 | 3.49 | 2.42 |
Currency Exchange Gain (Loss) | - | - | 5.37 | 0.7 | 9.44 | -2.56 |
Other Non Operating Income (Expenses) | -11.97 | -10.56 | -0.2 | -0.18 | -0.16 | -0.14 |
EBT Excluding Unusual Items | 42.81 | 33.17 | -6.44 | 27.86 | 68.23 | 84.17 |
Gain (Loss) on Sale of Investments | 16.71 | 7 | 4.97 | 5.58 | -0.1 | 0.4 |
Gain (Loss) on Sale of Assets | 0.04 | 0.04 | - | 0.01 | -0.07 | 0.05 |
Asset Writedown | -16.31 | -11.89 | -0.29 | -0.71 | - | -0.49 |
Other Unusual Items | - | - | 5.29 | 4.02 | 4.86 | 2.1 |
Pretax Income | 43.24 | 28.32 | 3.54 | 36.76 | 72.92 | 86.23 |
Income Tax Expense | -2.86 | -5.98 | -13.55 | -0.86 | 5.75 | 12.66 |
Net Income | 46.1 | 34.29 | 17.08 | 37.62 | 67.18 | 73.58 |
Net Income to Common | 46.1 | 34.29 | 17.08 | 37.62 | 67.18 | 73.58 |
Net Income Growth | 81.57% | 100.75% | -54.59% | -44.00% | -8.70% | 51.11% |
Shares Outstanding (Basic) | 139 | 137 | 142 | 139 | 111 | 105 |
Shares Outstanding (Diluted) | 145 | 143 | 142 | 139 | 111 | 105 |
Shares Change (YoY) | 6.38% | 0.38% | 2.17% | 26.04% | 5.66% | 1.58% |
EPS (Basic) | 0.33 | 0.25 | 0.12 | 0.27 | 0.61 | 0.70 |
EPS (Diluted) | 0.32 | 0.24 | 0.12 | 0.27 | 0.61 | 0.70 |
EPS Growth | 70.68% | 100.00% | -55.56% | -55.57% | -13.59% | 48.85% |
Free Cash Flow | 112.84 | 92.2 | -28.54 | -227.41 | -24.67 | 13.01 |
Free Cash Flow Per Share | 0.78 | 0.65 | -0.20 | -1.63 | -0.22 | 0.12 |
Dividend Per Share | - | - | 0.430 | 0.254 | 0.275 | - |
Dividend Growth | - | - | 69.42% | -7.61% | - | - |
Gross Margin | 28.30% | 27.42% | 23.98% | 28.41% | 36.42% | 37.98% |
Operating Margin | 6.93% | 6.34% | -1.63% | 5.44% | 12.58% | 19.41% |
Profit Margin | 6.67% | 4.98% | 3.14% | 7.68% | 14.03% | 16.42% |
Free Cash Flow Margin | 16.32% | 13.39% | -5.24% | -46.44% | -5.15% | 2.90% |
EBITDA | 77.17 | 72.19 | 17 | 47.41 | 76.6 | 99.57 |
EBITDA Margin | 11.16% | 10.49% | 3.12% | 9.68% | 16.00% | 22.22% |
D&A For EBITDA | 29.25 | 28.58 | 25.9 | 20.77 | 16.35 | 12.59 |
EBIT | 47.92 | 43.62 | -8.9 | 26.64 | 60.25 | 86.98 |
EBIT Margin | 6.93% | 6.34% | -1.63% | 5.44% | 12.58% | 19.41% |
Effective Tax Rate | - | - | - | - | 7.88% | 14.68% |
Revenue as Reported | - | - | 544.47 | 489.72 | 478.88 | 448.21 |
Advertising Expenses | - | - | 0.21 | 0.11 | 0.43 | 0.03 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.